Analysis of functional role of intereukin-6 secreted by tumor-associated macrophage in ovarian cancer ascites

无菌采集腹水，采用磁激活细胞分选(MACS)技术进行阳性选择，纯化CD11b阳性细胞(TAMs)。在Matrigel Boyden小室实验中，卵巢癌细胞系SKOV3ip1细胞与TAMS共培养可显著增强癌细胞的侵袭活性。这种增强可被抗白细胞介素6受体抗体(Tocilizumab)部分阻断。由于SKOV3ip1细胞不表达IL-6，TAMs分泌的IL-6在卵巢癌侵袭中起关键作用。在体内卵巢癌移植瘤中，腹腔注射Tocilizumab可显著减少腹膜播散和腹水形成。这些结果表明，靶向TAMS产生的IL-6可能是一种有希望的卵巢癌患者亚群的治疗方法。

Ascites were collected aseptically, and CD11b positive cells(TAMs) were purified by positive selection using magnetic-activate cell sorting(MACS) technology. Co-culture of ovarian cancer cell line, SKOV3ip1 cells, with TAMs significantly enhanced the invasive activity of cancer cells in Matrigel Boyden chamber assay. This enhancement was partially blolcked by the treatment of anti-interleukin(IL)-6 receptor antibody(Tocilizumab). Since SKOV3ip1 cells did not express IL-6 in mRNA and protein level, IL-6 secreted by TAMs were considered to play a key role in ovarian cancer invasion. In vivo ovarian cancer xenografts, i. p. treatment of Tocilizumab significantly reduced peritoneal dissemination and ascites formation. Those results suggested targeting IL-6 produced by TAMs could be a promising therapy for a subset of ovarian cancer patients.